126728-20-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloropyrido[2,3-d]pyrimidine is used as a building block in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of novel drugs, enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
2,4-DICHLOROPYRIDO[2,3-D]PYRIMIDINE is also used as a precursor in the development of agrochemicals, particularly in the creation of herbicides and pesticides. Its potential herbicidal and pesticidal properties make it a valuable component in the formulation of agricultural products designed to protect crops and enhance yield.
Used in Cancer Treatment Research:
2,4-Dichloropyrido[2,3-d]pyrimidine has been studied for its potential use in the treatment of cancer. Its unique chemical properties may contribute to the development of new therapeutic agents that target cancer cells, offering hope for improved cancer treatment options.
However, it is crucial to handle 2,4-Dichloropyrido[2,3-d]pyrimidine with caution due to its potential harmful effects. Ingestion or inhalation of 2,4-DICHLOROPYRIDO[2,3-D]PYRIMIDINE can be harmful, and it may cause skin and eye irritation. Proper safety measures should be taken during its synthesis, storage, and application to minimize risks.

InChI:InChI=1/C7H3Cl2N3/c8-5-4-2-1-3-10-6(4)12-7(9)11-5/h1-3H

Upstream product

• 21038-66-4 1H-Pyrido[2,3-d]pyrimidine-2,4-dione 
• 21038-66-4 2,4-dihydroxy-pyrido[2,3-d]pyrimidine 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 7463-30-1 N-(2-pyridyl-3-methyl)acetamide 

Downstream Products

• 91996-76-8 2-chloro-3H-pyrido[2,3-d]pyrimidine-4-thione 
• 864667-14-1 2-chloro-4-phenylsulfanyl-pyrido[2,3-d]pyrimidine 
• 864667-13-0 4-benzyloxy-2-chloro-pyrido[2,3-d]pyrimidine 
• 126728-09-4 4-(4-Oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-benzonitrile 
• 126728-06-1 N-[4-(4-Oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-acetamide 
• 126728-05-0 2-(4-Nitro-phenylamino)-3H-pyrido[2,3-d]pyrimidin-4-one 
• 126728-08-3 2-(4-Benzoyl-phenylamino)-3H-pyrido[2,3-d]pyrimidin-4-one 
• 126728-07-2 4-(4-Oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-benzenesulfonamide 
• 133223-98-0 2-chloro-4-(N-methylphenylamino)pyrido-[2,3-d]pyrimidine 
• 1245737-03-4 C₁₈H₁₉ClN₄ 
• 1335247-35-2 N,N'-bis[2-(4-bromophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride 
• 1335247-33-0 N,N'-bis(4-methoxybenzyl)pyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride 
• 1335247-30-7 N,N'-dibenzylpyrido[2,3-d]pyrimidine-2,4-diamine hydrochloride 
• 1381870-51-4 4-(4-methoxyphenyl)-2-(3-thienyl)pyrido[2,3-d]pyrimidine 

Relevant academic research and scientific papers

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

We describe a novel series of potent inhibitors of the kinase activity of mTOR. The compounds display good selectivity relative to other PI3K-related kinase family members and, in cellular assays, inhibit both mTORC1 and mTORC2 complexes and exhibit good antiproliferative activity.

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Compounds containing pyrimidine heterocyclic structures and preparation methods and applications thereof

Compounds containing pyrimidine heterocyclic structures and preparation methods and applications thereof, belonging to the field of pharmaceutical technology, the present invention relates to compounds containing pyrimidine heterocyclic structures shown i

Synthesis and structure-activity relationship of: N 4-benzylamine- N 2-isopropyl-quinazoline-2,4-diamines derivatives as potential antibacterial agents

A series of N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamine derivatives has been synthesized and tested for antibacterial activity against five bacterial strains. Twelve different substituents on the N4-benzylamine group have been investigated along with replacement of the quinazoline core (with either a benzothiophene or regioisomeric pyridopyrimidine ring systems). In order to develop structure activity relationships, all derivatives were tested for their antibacterial activities against Escherichia coli and Staphylococcus aureus via Kirby-Bauer assays and minimum inhibitory concentration assays. Eight of the most potent compounds against S. aureus and E. coli were also screened against one strain of methicillin-resistant S. aureus (MRSA), Staphylococcus epidermidis and Salmonella typhimurium to further examine their antibacterial activities. Lead compound A5 showed good activities with MICs of 3.9 μg mL-1 against E. coli, S. aureus and S. epidermidis and 7.8 μg mL-1 against MRSA. Selected front runners were also screened for their DMPK properties in vitro to assess their potential for further development.

2,4-quinazolinediamine derivatives, and preparation method and application thereof

The invention discloses 2,4-quinazolinediamine derivatives, and a preparation method and application thereof, belonging to the field of medicines and preparation and application thereof. The 2,4-quinazolinediamine derivatives comprises compounds as shown in a formula (I) which is described in the specification and a solvate, hydrate, tautomer and pharmaceutically acceptable salt thereof. Test results show that the 2,4-quinazolinediamine derivatives have strong Wolbachia resisting activity; and in the derivatives, 2-isopropylamido substitution has good effect, and compounds with better Wolbachia resisting activity can be obtained by changing a 4-amido group. The compounds have activity in resisting plasmodia, Wolbachia and bacteria.

PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF

Provided are piperazinyl pyrimidine derivatives of formula I having CCR4 antagonism, and the preparation method, pharmaceutical composition and use thereof in the preparation of a medicament. The medicament is useful for the treatment and preve

PIPERAZINYL PYRIMIDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF

Provided are piperazinyl pyrimidine derivatives of formula I having CCR4 antagonism, and the preparation method, pharmaceutical composition and use thereof in the preparation of a medicament. The medicament is useful for the treatment and preve

Discovery of 1-methyl-1 H-imidazole derivatives as potent Jak2 inhibitors

Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.

Novel quinazoline and pyrido[2,3-d]pyrimidine derivatives and their hydroselenite salts as antitumoral agents

A series of 22 quinazolines, pyrido[2,3-d]pyrimidines and their hydroselenite salts were synthesized with the aim of evaluating in vitro their cytotoxicity against PC-3 cell line and their antioxidant properties related to DPPH (1,1-diphenyl-2-picrylhydrazylradical) activity, showing some of them better profile than the respective controls. Three of these derivatives (5d, 6d and 7f) were selected in order to gain preliminary insights to establish the mechanism of action. Caspase-3 activity and cell cycle regulation studies revealed that compound 6d provoked an increase in caspase-3 level accompanied by cell cycle perturbation in a time-dependent manner.

Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure-Activity Relationship Study on Tofacitinib Bioisosteres

The Janus kinases (JAKs) are a family of cytosolic tyrosine kinases crucially involved in cytokine signaling. JAKs have been demonstrated to be valid targets in the treatment of inflammatory and myeloproliferative disorders, and two inhibitors, tofacitinib and ruxolitinib, recently received their marketing authorization. Despite this success, selectivity within the JAK family remains a major issue. Both approved compounds share a common 7H-pyrrolo[2,3-d]pyrimidine hinge binding motif, and little is known about modifications tolerated at this heterocyclic core. In the current study, a library of tofacitinib bioisosteres was prepared and tested against JAK3. The compounds possessed the tofacitinib piperidinyl side chain, whereas the hinge binding motif was replaced by a variety of heterocycles mimicking its pharmacophore. In view of the promising expectations obtained from molecular modeling, most of the compounds proved to be poorly active. However, strategies for restoring activity within this series of novel chemotypes were discovered and crucial structure-activity relationships were deduced. The compounds presented may serve as starting point for developing novel JAK inhibitors and as a valuable training set for in silico models.